ImmuPharma (LON:IMM) Trading Up 191.7% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s share price traded up 191.7% during trading on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). 104,299,430 shares were traded during mid-day trading, an increase of 470% from the average session volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).

ImmuPharma Stock Up 191.7 %

The business’s 50-day simple moving average is GBX 1.36 and its two-hundred day simple moving average is GBX 1.63. The stock has a market cap of £14.58 million, a P/E ratio of -350.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.